Virus therapy aims to boost chemo in tough pancreatic cancer

NCT ID NCT07701486

Not yet recruiting Disease control Sponsor: Theriva Biologics SL Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This trial tests whether a virus called VCN-01, given more frequently, is safe and tolerable when combined with standard chemotherapy (nab-paclitaxel and gemcitabine) for people with newly diagnosed stage IV pancreatic cancer that has spread. Participants receive up to three doses of VCN-01, each followed by two cycles of chemo. The study monitors safety and how the virus behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an oncolytic virus called VCN-01 (zabilugene almadenorepvec) plus standard chemotherapy (nab-paclitaxel and gemcitabine)
What this could lead to: If successful, this approach could improve outcomes for people with advanced pancreatic cancer by making chemotherapy more effective.
What could go wrong: This is a very early, small trial (6 people) focused on safety, not proof of effectiveness. The virus may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCTAL ADENOCARCINOMA OF THE PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm Neoplasm Metastasis pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCTAL ADENOCARCINOMA OF THE PANCREAS PANCREAS CANCER, METASTATIC PANCREAS CANCER, STAGE IV

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital 12 de Octubre

Madrid, Madrid, 28041, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.